You started Ozempic, lost weight steadily for a few months, and then — nothing. The scale stopped moving. You're still injecting every week, still eating less, but progress has stalled completely.

This is one of the most common experiences on GLP-1 medications. It's not a sign the drug stopped working, and it's not your fault. Here's what's actually happening and what the evidence says about moving through it.

Why plateaus happen on Ozempic

Your body is fighting back. When you lose weight, your metabolism adapts — it becomes more efficient and burns fewer calories at rest. At the same time, hunger hormones like ghrelin increase, driving appetite up. This is called metabolic adaptation, and it happens on every weight loss approach, not just GLP-1 medications.

4–8
Months into treatment is when most people report their first significant plateau — as metabolic adaptation catches up with the medication's appetite suppression.

GLP-1 medications like semaglutide (Ozempic, Wegovy) work by slowing gastric emptying and reducing appetite signals in the brain. But your body gradually recalibrates to a new set point. The medication is still working — it's just now competing with a more adapted metabolism.

Is it actually a plateau?

Before assuming you've stalled, check a few things:

Use our GLP-1 weight loss calculator to compare where you are against clinical trial averages for your medication and timeframe — this gives you useful context on whether your progress is actually behind or within normal range.

Evidence-based strategies to break through

1. Dose escalation (if eligible)

If you're not yet at the maximum dose for your medication, discuss escalation with your prescriber. The STEP trials showed dose-dependent weight loss — higher doses of semaglutide produced meaningfully greater results. Many people who plateau at 0.5mg or 1mg see renewed progress after moving to 2mg or 2.4mg (Wegovy dose).

2. Prioritise protein

Protein has the highest thermic effect of any macronutrient — your body burns more calories digesting it. More importantly, adequate protein (1.2–1.6g per kg of body weight) preserves muscle mass during weight loss, which keeps your resting metabolism higher. On GLP-1s, where total food intake drops significantly, protein often falls short without deliberate focus.

3. Resistance training

Cardio burns calories during exercise. Resistance training builds muscle, which burns calories continuously — even at rest. A 2024 study found that GLP-1 users who added resistance training lost significantly more fat mass and preserved more lean mass than those doing cardio alone. Even 2–3 sessions per week makes a measurable difference.

Important: GLP-1 medications can cause muscle loss alongside fat loss, particularly at higher doses. Resistance training and protein intake are especially important for preserving muscle during treatment.

4. Review total calorie intake

GLP-1 medications reduce appetite, but they don't make calorie balance irrelevant. As your body adapts, the hunger suppression effect can feel less dramatic than it did initially. Tracking food intake for 2–3 weeks often reveals calorie creep that's easy to miss.

5. Consider switching medications

If you've been on semaglutide for 12+ months and progress has completely stalled, tirzepatide (Mounjaro/Zepbound) may be worth discussing with your doctor. The 2025 SURMOUNT-5 head-to-head trial showed tirzepatide produced 47% greater relative weight loss than semaglutide. Some people who plateau on semaglutide respond strongly to the dual GIP/GLP-1 mechanism of tirzepatide.

What not to do

When to talk to your doctor

If you've been at a complete standstill for more than 3 months despite making dietary and exercise changes, it's worth a conversation with your prescriber. They can assess whether dose adjustment, medication switching, or investigation into other factors (thyroid, sleep apnoea, medications that cause weight gain) is appropriate.

A plateau isn't failure — it's a normal phase of the process. The people who break through it are the ones who treat it as a signal to adjust, not stop.